



Monday, June 2nd

Time	Session	Faculty
13:00-14:00	Conference opens (welcome, networking)	
14:00-14:10	Welcome and Introductions	Sebastian Wicha + Erin McCreary
	<i>The ABC of PK/PD</i>	
	<i>Moderator: Lisa Dumkow (Michigan, USA)</i>	
14:10-14:45	Basics of dosing (interactive session)	Sebastian Wicha
14:45-15:10	Preclinical in vitro infection models (HFIM for combination therapies)	Brian Tsuji
15:10-15:35	Preclinical in vitro infection models (Modeling framework for beta lactamase inhibitors)	Vincent Tam
15:35-15:45	Q&A	
15:45-16:10	Preclinical in vivo infection models	David Andes
16:10-16:40	BREAK AND NETWORKING	
	<i>Where do dosing regimens come from? PK/PD Modelling and Simulations</i>	
	<i>Moderator: Athena Hobbs (Tennessee, USA)</i>	
16:40-17:10	Mathematical modelling using preclinical data to predict dosing strategies	Cornelia Landersdorfer
17:10-17:40	Physiologically-based PK and population PK modelling - A primer	Gauri Rao
17:40-17:50	Q&A, Wrap Up	
18:00-?	Madison Student Union Terrace: Social	



Tuesday, June 3rd

Time	Session	Faculty
8:00-8:45	Coffee and Breakfast provided at Discovery Center	
8:45-8:50	Welcome	Erin McCreary
	<i>PK PD for Special populations</i>	
	<i>Moderator: Anne-Grete Martson (Netherlands)</i>	
8:50-9:20	Tissue penetration of antibiotics – from measurement to dose adaption	Markus Zeitlinger
9:20-9:50	Why do we need to reconsider standard dosing regimens in special populations?	Birgit Koch
9:50-10:00	Q&A	
10:00-10:30	BREAK AND NETWORKING	
	<i>Beta lactams for gram-negative pathogens</i>	

	Moderator: Cornelia Landersdorfer (Australia)	
10:30-11:00	Implementing beta lactam TDM across a system - operations and modeling	Ryan Shields and Jim Rhodes
11:00-11:25	Pivmecillinam for uUTI (and beyond?)	Thomas Tangden
11:25-11:50	PK PD of the oral carbapenems - what do we need to know	Maggie Monogue
11:50-12:15	Revisiting the breakpoints for the oral cephalosporins for systemic <i>Enterobacterales</i>	Jason Pogue
12:15-12:25	Q&A	
12:25-13:20	LUNCH	
	Gram positive updates	
	Moderator: Amit Pai (Michigan, USA)	
13:20-13:45	We implemented AUC-based vancomycin - now what? Lessons learned.	Marc Scheetz
13:45-14:10	Linezolid TDM - where have we come and where are we going?	Sonia Luque
14:10-14:35	Gram-positive potpourri (fixed dose daptomycin, TDM or unique dosing for oritavancin/dalbavancin)	Cecilia Volk
14:35-14:45	Q&A	
14:45-15:15	BREAK AND NETWORKING	
	Pharmacodynamic targets for treating complex pathogens – are we there yet?	
	Moderator: Tomefa Asempa (HHC Health)	
15:15-15:40	PKPD and Acinetobacter Susceptibility Breakpoints: A Framework for Holding ‘Older’ Drugs to the Same Standards as Newer Drugs	Alex Lepak
15:40-16:05	(Val)ganciclovir for cytomegalovirus	Erin McCreary
16:05-16:30	Trimethoprim/sulfamethoxazole for <i>Stenotrophomonas maltophilia</i>	Sam Aitken
16:30-16:40	Q&A	
16:40-17:00	BREAK AND NETWORKING	
17:00-17:30	Future perspectives – clinical breakpoints and dosing in 20 years from USA (clinical trials and regulatory approvals related to PK/PD)	Sujata Bhavnani
17:30-17:45	Q&A	
17:45-18:00	Closing remarks	Sebastian Wicha + Erin McCreary